Barchart.com
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc (NKGN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.1201 +0.0050 (+4.34%) 04/14/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.1201 unch (unch) 15:41 ET
News & Headlines for Mon, Apr 14th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition GlobeNewswire - Mon Apr 14, 7:00AM CDT

NKGN : 0.1201 (+4.34%)
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) GlobeNewswire - Mon Apr 7, 7:05AM CDT

NKGN : 0.1201 (+4.34%)
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) GlobeNewswire - Tue Mar 25, 7:05AM CDT

NKGN : 0.1201 (+4.34%)
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit GlobeNewswire - Thu Mar 13, 7:00AM CDT

NKGN : 0.1201 (+4.34%)
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented GlobeNewswire - Tue Mar 4, 12:00PM CST

NKGN : 0.1201 (+4.34%)
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program GlobeNewswire - Mon Mar 3, 7:00AM CST

NKGN : 0.1201 (+4.34%)
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program GlobeNewswire - Fri Feb 21, 7:00AM CST

NKGN : 0.1201 (+4.34%)
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site GlobeNewswire - Wed Feb 19, 7:00AM CST

NKGN : 0.1201 (+4.34%)
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease GlobeNewswire - Thu Feb 13, 7:00AM CST

NKGN : 0.1201 (+4.34%)
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease GlobeNewswire - Wed Feb 12, 7:00AM CST

NKGN : 0.1201 (+4.34%)

Barchart Exclusives

Should You Buy Apple Stock on the ‘Liberation Day’ Dip? Barchart - Mon Apr 14, 3:42PM CDT
Down almost 25% from all-time highs, Apple stock is unlikely to deliver outsized gains to long-term shareholders despite the ongoing pullback in valuation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot